Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...

The FDA accepts and grants priority review to BAYRY's sNDA for Kerendia to treat patients with a common form of heart failure ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...

The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...

Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.

Defyne Plastic Surgery is setting a new standard in the world of body contouring by becoming the first medical practice in Arizona to offer alloClae, the groundbreaking structural adipose filler that ...

Avado, a leading provider of professional learning, is introducing CIPD Level 5 Plus ? a premium offering for those pursuing their CIPD qualification. Building on the success of Avado's existing CIPD ...

In a report released on March 5, Christian Faitz from Kepler Capital maintained a Hold rating on Bayer (0P6S – Research Report), with a price ...

Bayer’s fourth-quarter earnings were in line ... Pharmaceuticals grew by 2.4%, with new drugs Nubeqa (prostate cancer) and Kerendia (metabolic disease) posting strong adjusted growth of 73% ...

Bayer AG (BAYRY) reports modest sales growth and debt reduction amid financial headwinds and strategic challenges.